Article Sidebar

Submitted
December 31, 2023
Accepted
December 31, 2023
Published
December 31, 2023
Download
PDF
Statistic
Read Counter : 388 Download : 235

Main Article Content

Abstract

Background: diabetes mellitus is a common disorder worldwide. Type 2 is the
commonest form of this disorder. Patients with DM type 2 have a higher
susceptibility to develop certain complications including diabetic peripheral
neuropathy which often leads to foot ulceration and consequently amputation. One
of the major contributers to the development of this complication is the oxidative
stress. Gamma glutamyl transferase (GGT) is an enzyme that increases in level
with increasing oxidative stress.
Aim of the Study: To determine the strength of association between serum GGT
and the presence of diabetic peripheral neuropathy, and to detect whether elevated
serum GGT can be used as an early marker for the development of diabetic
peripheral neuropathy.
Methodology: This study is a case-control study that included a total of 60
participants: 30 patients of type 2 DM with peripheral neuropathy (cases) and 30
patients of type 2 DM without peripheral neuropathy (controls). Data was collected
from Al-Sadr Medical City and Middle Euphrates Center for Neurological
Sciences (Al-Najaf – Iraq) during the period from November 2017 through January
2018.
Results: Statistical analysis of the data shown that there is a strong statistical
significance indicating significant relationship between elevated serum GGT levels
and the presence of peripheral neuropathy in study population (χ2 = 13.07 , d.f =
1 , P < 0.001).
Conclusion: Elevated level of serum GGT is associated with diabetic peripheral
neuropathy in patients with type 2 DM.

Keywords

Diabetes mellitus Gamma-glutamyltransferase neuropathy

Article Details

License

Copyright (c) 2023 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000
  2. and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
  3. Cho H. The Association between Serum GGT Concentration and Diabetic Peripheral Polyneuropathy in
  4. Type 2 Diabetic Patients. Korean Diabetes Journal. 2010;34(2):111-118.
  5. Hossain P, Kawar B, El Nahas M. Obesity and Diabetes in the Developing World — A Growing Challenge.
  6. New England Journal of Medicine. 2007;356(3):213-215.
  7. Iraq Family Health Survey 2006/7. Prevalence of non communicable diseases and risk factors in Iraq, A step
  8. wise approach. National survey implemented by Ministry of Health, Directorate of Public Health and Primary
  9. Health Care and Ministry of Planning and Development Cooperation in collaboration with World Health
  10. Organization (WHO)/Iraq-Baghdad, 2006/7.
  11. Olokoba A, Obateru O, Olokoba L. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical
  12. Journal. 2012;27(4):269-273.
  13. Piero M, Nzaro G, Njagi J. Diabetes mellitus – a devastating metabolic disorder. Asian Journal of
  14. Biomedical and Pharmaceutical Sciences. 2014;04 (40):1-7.
  15. Azevedo M, Alla S. Diabetes in sub-saharan Africa: Kenya, Mali, Mozambique, Nigeria, South Africa and
  16. Zambia. International Journal of Diabetes in Developing Countries. 2008 ;28(4):101-8.
  17. M. Wilson N, E. Wright D. Inflammatory Mediators in Diabetic Neuropathy. Journal of Diabetes &
  18. Metabolism. 2012;01(S5).
  19. Bhat M. Diabetic Neuropathy - A Review. European Journal of Biomedical and Pharmaceutical Sciences.
  20. ;2(5):1583-1602.
  21. Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R et al. Diabetic Neuropathies: A statement by
  22. the American Diabetes Association. Diabetes Care. 2005;28(4):956-962.
  23. Abdullah Q, Omer S, Mohammed M. Diabetic polyneuropathy: role of oxidative stress and inflammation.
  24. World journal of pharmacy and pharmaceutical sciences. 2015;4(2): 88-101.
  25. Al-Ani Y. Predicting Microvascular Complications in Diabetic Patients. Iraqi Journal of Medical Sciences.
  26. ;9(3):195-205.
  27. de M. Bandeira S, da Fonseca L, da S. Guedes G, Rabelo L, Goulart M, Vasconcelos S. Oxidative Stress as
  28. an Underlying Contributor in the Development of Chronic Complications in Diabetes Mellitus. International
  29. Journal of Molecular Sciences. 2013;14(2):3265-3284.
  30. Jyothirmayi B, Sanjayseth, Kaviarasi S, William E. Study of serum GGT levels and lipid profile in diabetic
  31. peripheral neuropathy, International Journal of Pharma and Bio Sciences. 2012;3(4):(B)995-1000
  32. Whitfield J. Gamma-glutamyl transferase. Critical Reviews in Clinical Laboratory Sciences. 2001;38:263–
  33. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic Fatty Liver
  34. Disease: A Feature of the Metabolic Syndrome. Diabetes. 2001;50(8):1844-1850.
  35. Meisinger C, Löwel H, Heier M, Schneider A, Thorand B. Serum
  36. γ-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population.
  37. Journal of Internal Medicine 2005;258:527-35.
  38. Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T
  39. et al. Subclinical Inflammation and Diabetic Polyneuropathy: MONICA/KORA Survey F3 (Augsburg,
  40. Germany). Diabetes Care. 2009;32(4):680-682.
  41. Boulton A, Malik R, Arezzo J, Sosenko J. Diabetic Somatic Neuropathies. Diabetes Care 2004;27(6):1458-
  42. Lee D, Gross M, Jacobs D. Association of Serum Carotenoids and Tocopherols with γ-Glutamyltransferase:
  43. The Cardiovascular Risk Development in Young Adults (CARDIA) Study. Clinical Chemistry 2004;50(3):582-
  44. Gordis L. Epidemiology. Philadelphia, Pennsylvania: Elsevier Saunders; 2014

Similar Articles

You may also start an advanced similarity search for this article.